Advertisement

ADVERTISEMENT

Chronic Lymphocytic Leukemia

Videos
John Byrd, MD, Discusses Acalabrutinib vs Ibrutinib for Patients With CLL
06/09/2021
Dr Byrd shares results from a phase 3 trial on acalabrutinib versus ibrutinib for patients with CLL. These data are being presented at the 2021 ASCO Annual Meeting.
Dr Byrd shares results from a phase 3 trial on acalabrutinib versus ibrutinib for patients with CLL. These data are being presented at the 2021 ASCO Annual Meeting.
Dr Byrd shares results from a...
06/09/2021
Oncology
Paolo Ghia, MD, PhD
Videos
Combo Therapy Demonstrates Durable Responses in Patients With CLL
06/07/2021
Paolo Ghia, MD, PhD, discusses the CAPTIVATE study of ibrutinib plus venetoclax in patients with CLL. These data are being presented at the 2021 ASCO Annual Meeting.
Paolo Ghia, MD, PhD, discusses the CAPTIVATE study of ibrutinib plus venetoclax in patients with CLL. These data are being presented at the 2021 ASCO Annual Meeting.
Paolo Ghia, MD, PhD, discusses...
06/07/2021
Oncology
Paul Barr, MD
Videos
Ibrutinib Therapy Demonstrates Sustained PFS, OS in Patients With CLL/SLL
06/04/2021
Paul Barr, MD, shares findings from the RESONATE-2 study of ibrutinib in patients with CLL/SLL. These data are being presented at the 2021 ASCO Annual Meeting.
Paul Barr, MD, shares findings from the RESONATE-2 study of ibrutinib in patients with CLL/SLL. These data are being presented at the 2021 ASCO Annual Meeting.
Paul Barr, MD, shares findings...
06/04/2021
Oncology
Conference Insider
Cirmtuzumab, Ibrutinib Therapy Well Tolerated in CLL/MCL
06/02/2021
Cirmtuzumab in combination with ibrutinib is a well-tolerated and active regimen for patients with b-cell lymphoid malignancies.
Cirmtuzumab in combination with ibrutinib is a well-tolerated and active regimen for patients with b-cell lymphoid malignancies.
Cirmtuzumab in combination with...
06/02/2021
Oncology
Conference Insider
Increased Risk for HZ Varies by Age, Treatment in Patients With CLL
05/28/2021
According to study findings presented at the 2021 ASCO Annual Meeting, patients with CLL are at an increased risk for herpes zoster when factoring in age and treatment regimens.
According to study findings presented at the 2021 ASCO Annual Meeting, patients with CLL are at an increased risk for herpes zoster when factoring in age and treatment regimens.
According to study findings...
05/28/2021
Oncology
Real-World Outcomes of First-Line Ibrutinib vs CIT for CLL
Interview
Real-World Outcomes of First-Line Ibrutinib vs CIT for CLL
12/16/2020
Lori Leslie, MD, discusses clinical outcomes among real-world patients with CLL given first-line therapy with ibrutinib or chemoimmunotherapy (CIT).
Lori Leslie, MD, discusses clinical outcomes among real-world patients with CLL given first-line therapy with ibrutinib or chemoimmunotherapy (CIT).
Lori Leslie, MD, discusses...
12/16/2020
Oncology
Othman Al-Sawaf, MD, Discusses Results From the Phase 3 CLL14 Trial
Videos
Othman Al-Sawaf, MD, Discusses Results From the Phase 3 CLL14 Trial
12/07/2020
Othman Al-Sawaf, MD, University Hospital of Cologne, Germany, discusses highlights from the phase 3 CLL14 trial, which looked at venetoclax plus obinutuzumab therapy for chronic lymphocytic leukemia (CLL). These data were presented at the...
Othman Al-Sawaf, MD, University Hospital of Cologne, Germany, discusses highlights from the phase 3 CLL14 trial, which looked at venetoclax plus obinutuzumab therapy for chronic lymphocytic leukemia (CLL). These data were presented at the...
Othman Al-Sawaf, MD, University...
12/07/2020
Oncology
Christopher Crane, MD, Debates Benefits of Long- vs Short-Course RT for Rectal Cancer
Podcasts
Christopher Crane, MD, Debates Benefits of Long- vs Short-Course RT for Rectal Cancer
07/14/2020
Christopher Crane, MD, debates the benefits of long-course radiation therapy over short-course for treatment of rectal cancer at the virtual 2020 Great Debates and Updates in GI Malignancies meeting.
Christopher Crane, MD, debates the benefits of long-course radiation therapy over short-course for treatment of rectal cancer at the virtual 2020 Great Debates and Updates in GI Malignancies meeting.
Christopher Crane, MD, debates...
07/14/2020
Oncology
Venetoclax Monotherapy Yields Deep Responses, Manageable Safety in CLL
Videos
Venetoclax Monotherapy Yields Deep Responses, Manageable Safety in CLL
06/29/2020
Arnon P. Kater, MD, PhD, discusses results from the phase 3b VENICE I trial, which evaluated the efficacy of venetoclax in patients with relapsed/refractory CLL.
Arnon P. Kater, MD, PhD, discusses results from the phase 3b VENICE I trial, which evaluated the efficacy of venetoclax in patients with relapsed/refractory CLL.
Arnon P. Kater, MD, PhD,...
06/29/2020
Oncology
Ibrutinib Plus Venetoclax Yields High Rates of Undetectable MRD in CLL
Videos
Ibrutinib Plus Venetoclax Yields High Rates of Undetectable MRD in CLL
06/22/2020
Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, discusses the results of the MRD cohort of the CAPTIVATE trial, a multicenter phase 2 trial evaluating ibrutinib plus venetoclax in CLL and SLL.
Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, discusses the results of the MRD cohort of the CAPTIVATE trial, a multicenter phase 2 trial evaluating ibrutinib plus venetoclax in CLL and SLL.
Constantine Tam, MBBS (Hons),...
06/22/2020
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

September 18 ⁠–⁠ September 20
September 20 ⁠–⁠ September 22
September 21 ⁠–⁠ September 22
AMP Europe
September 30 ⁠–⁠ October 2
October 1 ⁠–⁠ October 2
SAWC Fall
October 2 ⁠–⁠ October 5
October 5 ⁠–⁠ October 6
SMASH
October 14 ⁠–⁠ October 16
Lymphoma, Leukemia, and Myeloma
October 16 ⁠–⁠ October 19
October 19 ⁠–⁠ October 20
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use